236 related articles for article (PubMed ID: 19583681)
1. Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease type.
Yamamoto M; Kuzuya T; Baba H; Yamada K; Nabeshima T
J Clin Pharm Ther; 2009 Aug; 34(4):473-83. PubMed ID: 19583681
[TBL] [Abstract][Full Text] [Related]
2. Characterization of vancomycin pharmacokinetics in the adult acute myeloid leukemia population.
Jarkowski A; Forrest A; Sweeney RP; Tan W; Segal BH; Almyroudis N; Wang ES; Wetzler M
J Oncol Pharm Pract; 2012 Mar; 18(1):91-6. PubMed ID: 21521799
[TBL] [Abstract][Full Text] [Related]
3. Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations.
Thomson AH; Staatz CE; Tobin CM; Gall M; Lovering AM
J Antimicrob Chemother; 2009 May; 63(5):1050-7. PubMed ID: 19299472
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic modelling of gentamicin and vancomycin in patients with unstable renal function following cardiothoracic surgery.
Staatz CE; Byrne C; Thomson AH
Br J Clin Pharmacol; 2006 Feb; 61(2):164-76. PubMed ID: 16433871
[TBL] [Abstract][Full Text] [Related]
5. Influence of glomerular filtration rate on the clearance of vancomycin administered by continuous infusion in burn patients.
Dailly E; Le Floch R; Deslandes G; Pannier M; Jolliet P
Int J Antimicrob Agents; 2008 Jun; 31(6):537-9. PubMed ID: 18462925
[TBL] [Abstract][Full Text] [Related]
6. Urea kinetics and dialysis treatment time predict vancomycin elimination during high-flux hemodialysis.
Schaedeli F; Uehlinger DE
Clin Pharmacol Ther; 1998 Jan; 63(1):26-38. PubMed ID: 9465839
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of vancomycin in adult cancer patients.
Al-Kofide H; Zaghloul I; Al-Naim L
J Oncol Pharm Pract; 2010 Dec; 16(4):245-50. PubMed ID: 20015925
[TBL] [Abstract][Full Text] [Related]
8. Vancomycin pharmacokinetics in patients with severe burn injuries.
Dolton M; Xu H; Cheong E; Maitz P; Kennedy P; Gottlieb T; Buono E; McLachlan AJ
Burns; 2010 Jun; 36(4):469-76. PubMed ID: 19875238
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of high-dose methotrexate in Japanese adult patients with malignancies: a concurrent analysis of the serum and urine concentration data.
Fukuhara K; Ikawa K; Morikawa N; Kumagai K
J Clin Pharm Ther; 2008 Dec; 33(6):677-84. PubMed ID: 19138246
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of cefepime in neonates with severe nosocomial infections.
Lima-Rogel V; Medina-Rojas EL; Del Carmen Milán-Segovia R; Noyola DE; Nieto-Aguirre K; López-Delarosa A; Romano-Moreno S
J Clin Pharm Ther; 2008 Jun; 33(3):295-306. PubMed ID: 18452417
[TBL] [Abstract][Full Text] [Related]
11. Teicoplanin population pharmacokinetic analysis in hospitalized patients.
Soy D; López E; Ribas J
Ther Drug Monit; 2006 Dec; 28(6):737-43. PubMed ID: 17164688
[TBL] [Abstract][Full Text] [Related]
12. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients.
Lodise TP; Patel N; Lomaestro BM; Rodvold KA; Drusano GL
Clin Infect Dis; 2009 Aug; 49(4):507-14. PubMed ID: 19586413
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of gentamicin in hospitalized patients receiving once-daily dosing.
Xuan D; Nicolau DP; Nightingale CH
Int J Antimicrob Agents; 2004 Mar; 23(3):291-5. PubMed ID: 15164971
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic parameters of vancomycin in critically ill patients.
Llopis-Salvia P; Jiménez-Torres NV
J Clin Pharm Ther; 2006 Oct; 31(5):447-54. PubMed ID: 16958822
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinectics of vancomycin and amikacin in the subeschar tissue fluid in patients with severe burn.
Yang RH; Rong XZ; Hua R; Zhang T
Burns; 2009 Feb; 35(1):75-9. PubMed ID: 18789586
[TBL] [Abstract][Full Text] [Related]
16. A population pharmacokinetic approach to ceftazidime use in burn patients: influence of glomerular filtration, gender and mechanical ventilation.
Conil JM; Georges B; Lavit M; Laguerre J; Samii K; Houin G; Saivin S
Br J Clin Pharmacol; 2007 Jul; 64(1):27-35. PubMed ID: 17324245
[TBL] [Abstract][Full Text] [Related]
17. Vancomycin pharmacokinetics in infants: relationship to postconceptional age and serum creatinine.
Kildoo CW; Lin LM; Gabriel MH; Folli HL; Modanlou HD
Dev Pharmacol Ther; 1989; 14(2):77-83. PubMed ID: 2630235
[TBL] [Abstract][Full Text] [Related]
18. Effect of various estimates of renal function on prediction of vancomycin concentration by the population mean and Bayesian methods.
Tsuji Y; Hiraki Y; Mizoguchi A; Sadoh S; Sonemoto E; Kamimura H; Karube Y
J Clin Pharm Ther; 2009 Aug; 34(4):465-72. PubMed ID: 19583680
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of vancomycin in patients receiving extracorporeal membrane oxygenation.
Mulla H; Pooboni S
Br J Clin Pharmacol; 2005 Sep; 60(3):265-75. PubMed ID: 16120065
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of the selective serotonin 5-HT1A receptor partial agonist piclozotan.
Mondick JT; Oo C; Patel D; Fujitani T; Shimizu K; Barrett JS
Am J Ther; 2009; 16(2):106-15. PubMed ID: 19300037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
